PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS

NCT00439673 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

62

Enrollment

OTHER

Sponsor class

Conditions

Myelodysplastic Syndromes

Interventions

DRUG: 5-Azacytidine
DRUG: Valproic Acid
DRUG: ATRA

Sponsor

Gruppo Italiano Malattie EMatologiche dell'Adulto